Clinical Trials Logo

Filter by:
NCT ID: NCT03475537 Withdrawn - Clinical trials for Transcranial Direct Current Stimulation

tDCS in Patients With Disorders of Consciousness

Start date: April 15, 2018
Phase: N/A
Study type: Interventional

test

NCT ID: NCT03575494 Withdrawn - Dental Caries Clinical Trials

Relationship Between Oral Health Status and Unexplained Female Infertility in Turkish Population

Start date: April 15, 2018
Phase:
Study type: Observational

Periodontal diseases and dental caries are initiated by a pathogenic biofilm, in a susceptible host, affecting the tooth periodontium and hard tissues. Its possible association with many biologic systems has been studied. In this study, researchers investigated association between oral health and female infertility, and what is the biological rationale for such relationship.

NCT ID: NCT03501953 Withdrawn - Physical Activity Clinical Trials

Neurophysiological Mechanisms of Physical Activity Interventions in Unique Environments

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

This randomized intervention is designed to compare the influence of physical activity in natural and urban environments on cognitive and physical health. Half of the participants will participate in a six-week physical activity class based in a natural environment, and half of the participants will participate in a six-week physical activity class based in an indoor environment. The investigators hypothesize the nature-based intervention will produce lower cognitive fatigue (measured using neurophysiological measurements), better cognitive performance (measured using cognitive assessments), and increased physical fitness (measuring using fitness testing).

NCT ID: NCT03532204 Withdrawn - Colorectal Cancer Clinical Trials

Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer

OLIVER
Start date: April 15, 2019
Phase: N/A
Study type: Interventional

The role of radiotherapy in metastatic cancer has historically been limited to palliation while metastasectomy or radiofrequency has emerged as playing a major role in disease control. Although resection is the standard of care for liver metastasis, 80-90% of patients are not resectable at diagnosis in particular because of the presence of oligometastases. Factors that favour a truly oligometastatic state include a long latent interval between the treatment of the primary tumor and the appearance of metastases. Oligometastatic cancer is a very heterogeneous disease with respect to several factors including the location of the primary tumor. With the advent of extracranial stereotactic body radiation therapy (SBRT), higher biological equivalent doses can be safely delivered in 3 to 5 fractions, thus potentially ablating all the tissue in the treated area while protecting more efficiently the hosting organ and healthy tissues surrounding the tumors. In patients with liver oligometastases, in-field local control rates at 2 years range from 70% to 90% with less than 5% severe grade 3 or higher toxicity rates. Retrospective studies indicate that roughly 20% of the patients remain disease-free 2 to 4 years after SBRT. For patients treated with SBRT some authors found that half of the patients had either no metastatic progression or very little progression in terms of number and site of metastases. The patterns of failure after SBRT for oligometastases in one organ showed that 73% of patients eventually developed new metastases with higher than 80% occurring as new metastases in the same index organ. These findings support the idea of an oligometastatic state in which aggressive local therapy could improve progression-free survival (PFS). With this phase III study, we sought to evaluate the impact of SBRT on PFS at 2 years in patients with synchronous or metachronous liver-only oligometastases from colorectal cancers patients after a first line chemotherapy for metastatic disease but not having progressed during first line chemotherapy and up to 1 year

NCT ID: NCT03544073 Withdrawn - Infertility Clinical Trials

GnRH Agonist at Embryo Transfer: IVF Outcomes

GRAET
Start date: April 15, 2019
Phase: Phase 3
Study type: Interventional

In ART (assisted reproductive technology) cycles, embryos are transferred to a woman's uterus after in-vitro fertilization (IVF) in a laboratory. Usually, hormones (progesterone) are given to the patient after transferring the embryo, as a supplement, in order to mimic the natural hormones that would normally be secreted in an unassisted pregnancy. This study will identify whether additional gonadotropin-releasing hormone (GnRH-agonist) administration, a natural hormone secreted from the hypothalamus, will improve the clinical pregnancy and live birth rates when using IVF.

NCT ID: NCT03572257 Withdrawn - Delirium Clinical Trials

Quetiapine Treatment for Pediatric Delirium

Start date: April 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, double-blind, randomized controlled trial to begin determining the efficacy of quetiapine as a treatment for pediatric delirium in patients admitted to the pediatric intensive care unit (PICU)

NCT ID: NCT03708354 Withdrawn - Clinical trials for Postmenopausal Women

Tocotrienols for Skeletal Muscle Health

VitE-muscle
Start date: April 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Sarcopenia, defined as a reduction in muscle mass and strength, is a major health concern for postmenopausal women. Evidence suggests that lowering inflammation levels is an important strategy to help mitigate age-related muscle dysfunction and loss. In this pilot study, the investigators will study a tocotrienol (vitamin-E isomer) intervention for feasibility and quantify its effects on postmenopausal women with low muscle strength. A double blind, placebo controlled trial will be conducted on fifty-two qualified subjects. The participants will be assigned to placebo or tocotrienols for 24 weeks. All participants will receive an Omron Alvita Optimized Pedometer. The investigators will measure muscular endurance, strength, and size and gut microbiome profiles at 0, 12, and 24 weeks. In addition, the investigators will measure serum and muscle inflammatory levels at 0 and 24 weeks. All data will be analyzed statistically at p<0.05.

NCT ID: NCT03784989 Withdrawn - Stoma Ileostomy Clinical Trials

Post Market Clinical Follow-up Study Evaluating Performance and Safety of the SenSura® Mio Kids Device

Start date: April 15, 2019
Phase:
Study type: Observational

This is a post market clinical follow-up study and devices will carry the CE mark once the study is initiated. The investigational device is SenSura® Mio Kids, which is a flat ostomy device. The device is comprised by a baseplate connected to a bag. The coupling between baseplate and bag can be either welded together, referred to as a 1-piece (1P) system, or assembled as separate parts, referred to as a 2-piece (2P) system.

NCT ID: NCT03825783 Withdrawn - Clinical trials for Leukocyte Adhesion Defect - Type I

A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

The primary purpose of the Phase I portion of the study is to determine the safety profile and preliminary evidence of efficacy associated with infusion of autologous gene-corrected hematopoietic stem cells.

NCT ID: NCT03884296 Withdrawn - Influenza Clinical Trials

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

FLU-Tonsil
Start date: April 15, 2019
Phase: Phase 4
Study type: Interventional

This is one project of a larger ongoing study related to the immune system's response to the flu virus. This study is designed to investigate the immune response to a nasal flu immunization in tonsillar tissue compared to what can be measured in the blood.